Autologous chimeric antigen receptor T cell therapy - UTC Therapeutics
Latest Information Update: 09 Mar 2023
At a glance
- Originator UTC Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Haematological malignancies
Most Recent Events
- 01 Mar 2023 UTC Therapeutics withdraws a phase I trial for Hematological malignancies and Lymphoid malignancies prior to enrollment (Metastatic, Second-line therapy or greater) in China (IV, Infusion) (NCT05513612)
- 16 Sep 2021 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater) in China (IV) (NCT05528887)